Patents by Inventor David J. Cosman

David J. Cosman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20040235058
    Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.
    Type: Application
    Filed: June 23, 2004
    Publication date: November 25, 2004
    Inventors: David J. Cosman, Jurgen Mullberg, William C. Fanslow, Marek Kubin, Richard Jeffrey Armitage
  • Patent number: 6774224
    Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.
    Type: Grant
    Filed: August 5, 2002
    Date of Patent: August 10, 2004
    Assignee: Immunex Corporation
    Inventors: David J. Cosman, Jurgen Mullberg, William C. Fanslow, III, Marek Kubin, Richard Jeffrey Armitage
  • Publication number: 20040152161
    Abstract: This invention relates to human and murine HPR1 and human and murine HPR2 polypeptides, new members of the hematopoietin receptor polypeptide family; to methods of making such HPR1 and HPR2 polypeptides; to non-human mammals in which the endogenous genomic sequences encoding HPR1 and/or HPR2 polypeptides have been partially or completely inactivated; to methods of using HPR1 or HPR2 polypeptides to identify compounds that alter HPR1 or HPR2 polypeptide activities; and to methods of preparing medicaments for and/or treating conditions associated with hematopoietin receptor function.
    Type: Application
    Filed: November 14, 2003
    Publication date: August 5, 2004
    Applicant: Immunex Corporation
    Inventors: David J. Cosman, Bruce A. Mosley, Robert F. DuBose, Steven R. Wiley
  • Publication number: 20040138126
    Abstract: A new family of immunoreceptor molecules of the immunoglobulin superfamily, (LIR) polypeptides is described. Disclosed are sequences encoding LIR family members and their deduced amino acid sequences, polypeptides encoded by DNA that hybridize to oligonucleotide probes having defined sequences, processes for producing polypeptides of the LIR family, and antagonistic antibodies to LIR family members. LIR family members can be used to treat autoimmune diseases and disease states associated with suppressed immune function.
    Type: Application
    Filed: December 22, 2003
    Publication date: July 15, 2004
    Applicant: Immunex Corporation
    Inventor: David J. Cosman
  • Patent number: 6716587
    Abstract: Mammalian Interleukin-4 receptor proteins, DNAs and expression vectors encoding mammalian IL-4 receptors, and processes for producing mammalian IL-4 receptors as products of cell culture, are disclosed. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.
    Type: Grant
    Filed: March 22, 2002
    Date of Patent: April 6, 2004
    Assignee: Immunex Corporation
    Inventors: Bruce A. Mosley, David J. Cosman, Linda S. Park, M. Patricia Beckmann, Carl J. March, Rejean Idzerda
  • Patent number: 6703487
    Abstract: There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed.
    Type: Grant
    Filed: April 27, 2001
    Date of Patent: March 9, 2004
    Assignee: Immunex Corporation
    Inventors: Timothy A. Bird, David J. Cosman
  • Publication number: 20040034199
    Abstract: There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed.
    Type: Application
    Filed: July 29, 2003
    Publication date: February 19, 2004
    Inventors: Timothy A Bird, David J. Cosman
  • Patent number: 6653447
    Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.
    Type: Grant
    Filed: March 13, 2000
    Date of Patent: November 25, 2003
    Assignee: Immunex Corporation
    Inventors: David J. Cosman, Jurgen Mullberg, William C. Fanslow, III, Marek Kubin, Richard Jeffrey Armitage
  • Publication number: 20030195337
    Abstract: ULBP4, a novel member of the ULBP family has been isolated and characterized. ULBP4 is a useful activator of immune effector cells, particularly of NK cells.
    Type: Application
    Filed: October 4, 2002
    Publication date: October 16, 2003
    Inventor: David J. Cosman
  • Publication number: 20030185821
    Abstract: Mammalian Interleukin-4 receptor proteins, DNAs and expression vectors encoding mammalian IL-4 receptors, and processes for producing mammalian IL-4 receptors as products of cell culture, are disclosed. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.
    Type: Application
    Filed: March 22, 2002
    Publication date: October 2, 2003
    Applicant: Immunex Corporation
    Inventors: Bruce A. Mosley, David J. Cosman, Linda S. Park, M. Patricia Beckman, Carl J. March, Rejean Idzerda
  • Publication number: 20030165945
    Abstract: There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed.
    Type: Application
    Filed: December 11, 2002
    Publication date: September 4, 2003
    Inventors: Timothy A. Bird, David J. Cosman, Xiaoxia Li
  • Publication number: 20030166073
    Abstract: A new family of immunoreceptor molecules of the immunoglobulin superfamily, (LIR) polypeptides is described. Disclosed are sequences encoding LIR family members and their deduced amino acid sequences, polypeptides encoded by DNA that hybridize to oligonucleotide probes having defined sequences, processes for producing polypeptides of the LIR family, and antagonistic antibodies to LIR family members. LIR family members can be used to treat autoimmune diseases and disease states associated with suppressed immune function.
    Type: Application
    Filed: May 8, 2002
    Publication date: September 4, 2003
    Applicant: Immunex Corporation
    Inventor: David J. Cosman
  • Publication number: 20030147847
    Abstract: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the surface of human B cell lymphomas. Mammalian forms of ULBP polypeptide in isolated or purified forms are provided. In addition, isolated nucleic acids encoding ULBP polypeptides and expression vectors comprising a cDNA encoding ULBP polypeptides are provided. The ULBP polypeptides can be isolated or synthesized and used to prepare antibodies, and in particular monoclonal antibodies, against the polypeptides. The antibodies, in turn, are useful for detecting the presence of ULBP polypeptides in human cell samples, which can be correlated with the existence of a malignant condition in a patient.
    Type: Application
    Filed: August 5, 2002
    Publication date: August 7, 2003
    Applicant: Immunex Corporation
    Inventors: David J. Cosman, Jurgen Mullberg, William C. Fanslow, Marek Kubin, Richard Jeffrey Armitage
  • Publication number: 20030109003
    Abstract: A novel polypeptide functions as the &bgr; chain of an oncostatin M receptor and is thus designated OSM-R&bgr;. Heterodimeric receptor proteins comprising OSM-R&bgr; and gp130 bind oncostatin M and find use in inhibiting biological activities mediated by oncostatin M.
    Type: Application
    Filed: December 6, 2002
    Publication date: June 12, 2003
    Applicant: Immunex Corporation
    Inventors: Bruce Mosley, David J. Cosman
  • Patent number: 6548655
    Abstract: Mammalian Interleukin-4 receptor proteins, DNAs and expression vectors encoding mammalian IL-4 receptors, and processes for producing mammalian IL-4 receptors as products of cell culture, are disclosed. A method for suppressing an IL-4-dependent immune or inflammatory response in a mammal, including a human, by administering an effective amount of soluble IL-4 receptor (sIL-4R) and a suitable diluent or carrier.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: April 15, 2003
    Assignee: Immunex Corporation
    Inventors: Bruce Mosley, David J. Cosman, Linda Park, M. Patricia Beckmann, Carl J. March, Rejean Idzerda
  • Publication number: 20030060616
    Abstract: Type II IL-1 receptor (type II IL-1R) proteins, DNAs and expression vectors encoding type II IL-1R, and processes for producing type II IL-1R as products of recombinant cell culture, are disclosed.
    Type: Application
    Filed: July 19, 2002
    Publication date: March 27, 2003
    Inventors: John E. Sims, David J. Cosman, Stephen D. Lupton, Bruce A. Mosley, Steven K. Dower
  • Publication number: 20030059871
    Abstract: This invention relates to human and murine HPR1 and human and murine HPR2 polypeptides, new members of the hematopoietin receptor polypeptide family; to methods of making such HPR1 and HPR2 polypeptides; to non-human mammals in which the endogenous genomic sequences encoding HPR1 and/or HPR2 polypeptides have been partially or completely inactivated; to methods of using HPR1 or HPR2 polypeptides to identify compounds that alter HPR1 or HPR2 polypeptide activities; and to methods of preparing medicaments for and/or treating conditions associated with hematopoietin receptor function.
    Type: Application
    Filed: October 5, 2001
    Publication date: March 27, 2003
    Inventors: David J. Cosman, Bruce A. Mosley, Timothy A. Bird, Robert F. DuBose, Steven R. Wiley
  • Publication number: 20030060614
    Abstract: A new family of immunoreceptor molecules of the immunoglobulin superfamily, (LIR) polypeptides is described. Disclosed are sequences encoding LIR family members and their deduced amino acid sequences, polypeptides encoded by DNA that hybridizes to defined nucleotide sequences, processes for producing polypeptides of the LIR family, and specific antibodies directed against LIR polypeptides. LIR family members can be used to treat autoimmune diseases and disease states associated with suppressed immune function.
    Type: Application
    Filed: May 2, 2002
    Publication date: March 27, 2003
    Applicant: Immunex Corporation
    Inventors: David J. Cosman, Dirk M. Anderson, Luis G. Borges
  • Patent number: 6524817
    Abstract: A novel polypeptide functions as the &bgr; chain of an oncostatin M receptor and is thus designated OSM-R&bgr;. Heterodimeric receptor proteins comprising OSM-R&bgr; and gp130 bind oncostatin M and find use in inhibiting biological activities mediated by oncostatin M.
    Type: Grant
    Filed: December 6, 1999
    Date of Patent: February 25, 2003
    Assignee: Immunex Corporation
    Inventors: Bruce Mosley, David J. Cosman
  • Patent number: 6521740
    Abstract: Type II IL-1 receptor (type II IL-1R) proteins, DNAs and expression vectors encoding type II IL-1R, and processes for producing type II IL-1R as products of recombinant cell culture, are disclosed.
    Type: Grant
    Filed: May 16, 1995
    Date of Patent: February 18, 2003
    Assignee: Immunex Corporation
    Inventors: John E. Sims, David J. Cosman, Stephen D. Lupton, Bruce A. Mosley, Steven K. Dower